Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine)

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 777-782

  Lawrence, Theodore S ^a   Chang, Emily Y ^a   Hahn, Tina M ^a   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; COLON CARCINOMA; DNA REPLICATION; DRUG HALF LIFE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; COBALT RADIOISOTOPES; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA DAMAGE; DNA FRAGMENTATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0030922494     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Moore, M., Andersen, J., Burris, H., Tarassoff, P., Green, M., Casper, E., Portenoy, R., Modiano, M., Cripps, C., and Nelson, R. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 14: A473, 1995.
2. Rothenberg, M. L., Moore, M. J., Cripps, M. D., Anderson, J. S., Portenoy, R. K., Burris, H. A., and Green, M. R. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 14: 347-353, 1996.
3. Carmichael, J., Allerheiligen, S., and Walling, J. A Phase I/II study of gemcitabine (Gem) and carboplatin (CBP) in NSCLC. Proc. Am. Soc. Clin. Oncol., 14: A1065, 1995.
4. Sandler, A. B., Ansari, R., McClean, J., Fisher, W., Door, A., and Einhorn, L. H. A. Hoosier oncology group Phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 14: A1089, 1995.
5. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
6. Baker, C. H., Banzon, J., Bollinger, J. M., Stubbe, J., Samano, V., Robins, M. J., Lippert, B., Jarvi, E., and Resvick, R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
7. Shewach, D. S., Hahn, T. M., Chang, E., Hertel, L. W., and Lawrence, T. S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res., 54: 3218-3223, 1994.
8. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,-2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
9. Ruiz van Haperen, V. W. T., Veerman, G., Vermorken, J. B., and Peters, G. J. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol., 46: 762-766, 1993.
10. Schy, W. E., Hertel, L. W., Kroin, J. S., Bloom, L. B., Goodman, M. F., and Richardson, F. C. Effect of a template-located 2′, 2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′-5′ exonuclease-) fragment. Cancer Res., 53: 4582-4587, 1993.
11. Rockwell, S., and Grindey, G. B. Effect of 2,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res., 4: 151-155, 1992.
12. Lawrence, T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W., and Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys., 34: 867-872, 1996.
13. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
14. Heinemann, V., Xu, Y-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., and Plunkett, W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res., 52: 533-539, 1992.
15. Fertil, B., Dertinger, H., Courdi, A., and Malaise, E. P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat. Res., 99: 73-84, 1984.
16. Tang, H-Y., Davis, M. A., Strickfaden, S. M., Maybaum, J., and Lawrence, T. S. Influence of cell cycle phase on radiation-induced cytotoxicity and DNA damage in human colon cancer (HT29) and Chinese hamster ovary cells. Radiat. Res., 138 (Suppl.): S109-S112, 1994.
17. Hoy, C. A., Seamer, L. C., and Schimke, R. T. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry, 10: 718-725, 1989.
18. Lawrence, T. S., Normolle, D. P., Davis, M. A., and Maybaum, J. The use of biphasic linear ramped pulsed field gel electrophoresis to quantify DNA damage based on fragment size distribution. Int. J. Radiat. Oncol. Biol. Phys., 27: 659-663, 1993.
19. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., Raber, M. N., and Plunkett, W. P. A. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 9: 491-498, 1991.
20. Grunewald, R., Abbruzzese, J. L., Tarassoff, P., and Plunkett, W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharmacol., 27: 258-262, 1991.
21. 125I decay. Int. J. Radiat. Oncol. Biol. Phys., 59: 343-357, 1991.